BIOVENTIX PLC
Bioventix plc
("Bioventix" or the "Company")
Director/PDMR Shareholding
Bioventix plc (BVXP), a UK company specialising in the development and
commercial supply of high-affinity monoclonal antibodies for application in
clinical diagnostics, was notified on 19 October 2017 of the following
transactions in its ordinary shares of 5 pence each ("Ordinary Shares"):
Director Position Ordinary Sale price Ordinary Percentage
Shares per Shares held of issued
sold Ordinary subsequently share
Share capital held
subsequently
Ian Nicholson and Non-Executive 5,000 2400.75p 18,000 0.4%
Persons Closely Chairman
Associated
Peter Harrison and CEO 80,000 2425.00p 428,176 8.3%
Persons Closely
Associated
Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them
Details of the person discharging managerial responsibilities /
person closely associated
a) Names Ian Nicholson (Non-Executive Chairman)
Catherine Nicholson (PCA with Ian Nicholson)
Peter Harrison (CEO)
Reason for the Notification
a) Position/status See 1(a) above, all are PDMR's or PCA's of
PDMR's
b) Initial notification/ Initial notification
Amendment
Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Bioventix plc
b) LEI 213800225MHX7LZQY108
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been conducted
a) Description of the Ordinary shares of 5 pence ("Ordinary
Financial instrument, Shares")
type of instrument
Identification code GB00B4QVDF07
b) Nature of the In each case, sale of Ordinary Shares
transaction
c) Price(s) and volume(s) Ian Nicholson:
Price(s) Volume(s)
2400.75p 2,500
Catherine Nicholson:
Price(s) Volume(s)
2400.75p 2,500
Peter Harrison:
Price(s) Volume(s)
2425.00p 80,000
d) Aggregated information: See 4(c)
e) Date of the transaction 19 October 2017
f) Place of the London Stock Exchange, AIM Market (XLON)
transaction
For further information please contact:
Bioventix plc Tel: 01252 728 001
Peter Harrison Chief Executive Officer
finnCap Ltd Tel: 020 7220 0500
Geoff Nash/Simon Hicks Corporate Finance
Stephen Norcross Corporate Broking
About Bioventix plc:
Bioventix (www.bioventix.com) specialises in the development and commercial
supply of high-affinity monoclonal antibodies with a primary focus on their
application in clinical diagnostics, such as in automated immunoassays used in
blood testing. The antibodies created at Bioventix are generated in sheep and
are of particular benefit where the target is present at low concentration and
where conventional monoclonal or polyclonal antibodies have failed to produce a
suitable reagent. Bioventix currently offers a portfolio of antibodies to
customers for both commercial use and R&D purposes, for the diagnosis or
monitoring of a broad range of conditions, including heart disease, cancer,
fertility, thyroid function and drug abuse. Bioventix currently supplies
antibody products and services to the majority of multinational clinical
diagnostics companies. Bioventix is based in Farnham, UK and its shares are
traded on AIM under the symbol BVXP.
Bioventix : Director/PDMR Shareholding
October 20, 2017 at 05:10 am EDT
Share
Share
© PRNewswire - 2017
